Co-administration of THC and MDMA ('Ecstasy') synergistically disrupts memory in rats

Neuropsychopharmacology

Volumn 30, Issue 8, 2005, Pages 1475-1482

  Young, June M ^a   McGregor, Iain S ^b   Mallet, Paul E ^a  

^a UNIVERSITY OF NEW ENGLAND   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Drug interactions; Maze learning; Memory; N methyl 3,4 methylenedioxyamphetamine; Rats; Tetrahydrocannabinol

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DRONABINOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG POTENTIATION; MALE; MAZE TEST; MEMORY DISORDER; NONHUMAN; PRIORITY JOURNAL; RAT; SPATIAL DISCRIMINATION; WORKING MEMORY;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; DISCRIMINATION (PSYCHOLOGY); DRUG COMBINATIONS; DRUG SYNERGISM; HALLUCINOGENS; MALE; MAZE LEARNING; MEMORY; MEMORY DISORDERS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, WISTAR; SPATIAL BEHAVIOR; TETRAHYDROCANNABINOL;

EID: 23844520957     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300692     Document Type: Article

References (55)

1. Acquas E, Marrocu P, Pisanu A, Cadoni C, Zernig G, Saria A et al (2001a). Intravenous administration of ecstasy (3,4-methylene-dioxymethamphetamine) enhances cortical and striatal acetylcholine release in vivo. Eur J Pharmacol 418: 207-211.
2. 9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study. Eur J Pharmacol 419: 155-161.
3. Ameri A (1999). The effects of cannabinoids on the brain. Progr Neurobiol 58: 315-348.
4. Barrionuevo M, Aguirre N, Del Rio J, Lasheras B (2000). Serotonergic deficits and impaired passive-avoidance learning in rats by MDEA: a comparison with MDMA. Pharmacol Biochem Behav 65: 233-240.
5. 2+ connection in dopamine signaling. Trends Pharmacol Sci 24: 486-492.
6. Bolla KI, McCann UD, Ricaurte GA (1998). Memory impairment in abstinent MDMA ('Ecstasy') users. Neurology 51: 1532-1537.
7. Boot BP, McGregor IS, Hall W (2000). MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. Lancet 355: 1818-1821.
8. Braida D, Pozzi M, Cavallini R, Sala M (2002). 3,4- Methylenedioxymethamphetamine (Ecstasy) impairs eight-arm radial maze performance and arm entry pattern in rats. Behav Neurosci 116: 298-305.
9. 9-tetrahydrocannabinol in the nucleus accumbens of rat: an in vivo microdialysis study. Neurosci Lett 129: 175-179.
10. Christophersen AS (2000). Amphetamine designer drugs-an overview and epidemiology. Toxicol Lett 112: 127-131.
11. Climko RP, Roehrich H, Sweeney DR, Al-Razi J (1986). Ecstasy: a review of MDMA and MDA. Int J Psychiatry Med 16: 359-372.
12. Cole JC, Sumnall HR (2003). The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev 27: 199-217.
13. Croft RJ, Mackay AJ, Mills ATD, Gruzelier JGH (2001). The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology 153: 373-379.
14. Daumann J, Schnitker R, Weidemann J, Schnell K, Thron A, Gouzoulis-Mayfrank E (2003). Neural correlates of working memory in pure and polyvalent ecstasy (MDMA) users. NeuroReport 14: 1983-1987.
15. Diana M, Melis M, Gessa GL (1998). Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. Eur J Neurosci 10: 2825-2830.
16. Downing J (1986). The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 18: 335-340.
17. 9-tetrahydrocannabinol-induced impairment of spatial memory. Eur J Pharmacol 445: 221-229.
18. Essman EJ (1984). Marijuana intoxication in rats: interruption of recent memory and effect on brain concentration of delta-9-tetrahydrocannabinol. Psychol Bull 55: 563-567.
19. Fischer HS, Zernig G, Schatz DS, Kumpel C, Saria A (2000). MMA ('ecstasy') enhances basal acetylcholine release in brain slices of the rat striatum. Eur J Neurosci 12: 1385-1390.
20. Frederick DL, Paule MG (1997). Effects of MDMA on complex brain function in laboratory animals. Neurosci Biobehav Rev 21: 67-78.
21. Gaoni Y, Mechoulam R (1964). Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86: 1646-1647.
22. Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert H-J et al (2000). Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry 68: 719-725.
23. Herkenham M, Lynn AB, Little M, Johnson R, Melvin L, de Costa BR et al (1990). Cannabinoid receptor localisation in brain. Proc Natl Acad Sci USA 87: 1932-1936.
24. Hermann H, Marsicano G, Lutz B (2002). Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109: 451-460.
25. Heyser CJ, Hampson RE, Deadwyler SA (1993). Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J Pharmacol Exp Therap 264: 294-307.
26. Jacobsen LK, Mencl WE, Pugh KR, Skudlarski P, Krystal JH (2004). Preliminary evidence of hippocampal dysfunction in adolescent MDMA ('ecstasy') users: possible relationship to neurotoxic effects. Psychopharmacology 173: 383-390.
27. 9-Tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA 966. Neuropsychopharmacology 16: 426-432.
28. 9-Tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology 126: 125-131.
29. Mallet PE, Beninger RJ (1993). The double Y-maze as a tool for assessing memory in rats. Neurosci Protocols 93: 01-11.
30. Mallet PE, Beninger RJ (1996). The endogenous cannabinoid receptor agonist anandamide impairs memory in rats. Behav Pharmacol 7: 276-284.
31. 9-tetrahydrocannabinol or anandamide. Psychopharmacology 140: 11-19.
32. Mason KI, Mallet PE, Jhamandas K, Boegman RJ, Beninger RJ (1999). Nucleus basalis injections of N-methyl-D-aspartate enhance memory of rats in the double Y-maze. Brain Res Bull 48: 65-71.
33. May R, Hunter M, Gabriel R (1993). NPFact 1.0. http://home. utah-inter.net/rmay/npstat.html.
34. 9 -tetrahydrocannabinol on short-term memory in the rat. Physiol Behav 57: 177-179.
35. Nakamura EM, da Silva EA, Concilio GV, Wilkinson DA, Masur J (1991). Reversible effects of acute and long-term administration of Δ-9- tetrahydrocannabinol (THC) on memory in the rat. Drug Alcohol Depend 28: 167-175.
36. 9-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in the T-maze. Neuropharmacology 41: 392-399.
37. Parrott AC, Lasky J (1998). Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology 139: 261-268.
38. Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes K (1998). Cognitive performance in recreational users of MDMA or 'ecstasy': evidence for memory deficits. J Psychopharmacol 12: 79-83.
39. Parrott AC, Sisk E, Turner JJD (2000). Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. Drug Alcohol Depend 60: 105-110.
40. 9-Tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res 948: 155-158.
41. Reneman L, Booij J, Schmand B, van den Brink W, Gunning B (2000). Memory disturbances in 'Ecstasy' users are correlated with an altered brain serotonin neurotransmission. Psychopharmacology 148: 322-324.
42. Ricaurte GA, Markowska AL, Wenk GL, Hatzidimitriou G, Wlos J, Olton DS (1993). 3,4-Methylenedioxymethamphetamine, serotonin and memory. J Pharmacol Exp Therap 266: 1097-1105.
43. Roiser JP, Sahakian BJ (2003). Relationship between ecstasy use and depression: a study controlling for poly-drug use. Psychopharmacology 173: 411-417.
44. Schifano F, Oyefeso A, Corkery J, Cobain K, Jambert-Gray R, Martinotti G et al (2003). Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996-2002. Hum Psychopharmacol Clin Exp 18: 519-524.
45. Shankaran M, Gudelsky GA (1998). Effect of 3,4- methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin. Pharmacol Biochem Behav 61: 361-366.
46. Smart RG, Ogborne AC (2000). Drug use and drinking among students in 36 countries. Addict Behav 25: 455-460.
47. Smith CG, Beninger RJ, Mallet PE, Jhamandas K, Boegman RJ (1994). Basal forebrain injections of the benzodiazepine partial inverse agonist FG 7142 enhance memory of rats in the double Y-maze. Brain Res 666: 61-67.
48. Tancer M, Johanson C-E (2003). Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend 72: 33-44.
49. Topp L, Hando J, Dillon P, Roche A, Solowij N (1999). Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 55: 105-115.
50. Turner C, Russell A, Brown W (2003). Prevalence of illicit drug use in young Australian women, patterns of use and associated risk factors. Addiction 98: 1419-1426.
51. 9 THC on spatial reference and working memory in mice. Psychopharmacology 157: 142-150.
52. Verheyden SL, Henry JA, Curran HV (2003). Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users. Hum Psychopharmacol Clin Exp 18: 507-517.
53. Vollenweider FX, Gamma A, Liechti M, Huber T (1998). Psychological and cardiovascular effects and short-term sequelae of MDMA ('Ecstasy') in MDMA-naive healthy volunteers. Neuropsychopharmacology 19: 241-251.
54. White SR, Obradovic KM, Imel KM, Wheaton MJ (1996). The effects of methylenedioxymethamphetamine (MDMA, 'Ecstasy') on monoaminergic neurotransmission in the central nervous system. Progr Neurobiol 49: 455-479.
55. Winstock AR, Griffiths P, Stewart D (2001). Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 64: 9-17.